The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...